Cargando…

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®

INTRODUCTION: Personalized therapy for patients with COPD requires appropriate choice of drug and delivery device. Inhalers and nebulizers vary in their drug delivery characteristics, particularly the need for passive or active patient inhalation for appropriate drug dispersal and delivery. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohar, Jill A., Bauer, Andrea, Sharma, Sanjay, Sanjar, Shahin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672140/ https://www.ncbi.nlm.nih.gov/pubmed/32809156 http://dx.doi.org/10.1007/s41030-020-00125-6

Ejemplares similares

Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015)

Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2016)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study
por: Trotta, Francesco, et al.
Publicado: (2017)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies
por: ZuWallack, Richard, et al.
Publicado: (2014)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch
por: Hanada, Soichiro, et al.
Publicado: (2015)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
por: Ohar, Jill, et al.
Publicado: (2018)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
por: Siler, Thomas M., et al.
Publicado: (2021)

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair(®) versus HandiHaler(®) in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial
por: Yildiz, Pinar, et al.
Publicado: (2016)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial
por: Altman, Pablo, et al.
Publicado: (2018)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
por: Donohue, James F., et al.
Publicado: (2017)

Extended Pharmacopeial Characterization of Surfactant Aerosols Generated by a Customized eFlow Neos Nebulizer Delivered through Neonatal Nasal Prongs
por: Bianco, Federico, et al.
Publicado: (2020)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer
por: Abd-Elaziz, Khalid, et al.
Publicado: (2020)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
por: Donohue, James F, et al.
Publicado: (2020)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
por: Hanania, Nicola A, et al.
Publicado: (2021)

Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
por: Stephenson, Judith J, et al.
Publicado: (2020)

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis
por: Khoo, Jun Keng, et al.
Publicado: (2020)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease
por: Jayanthi, Nalini, et al.
Publicado: (2022)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

Aerosolization Performance of Jet Nebulizers and Biopharmaceutical Aspects
por: Adorni, Greta, et al.
Publicado: (2019)

Aerosols, airflow, and airspace contamination during laparoscopy
por: Hardy, N, et al.
Publicado: (2021)

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study
por: LaForce, Craig, et al.
Publicado: (2016)

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
por: Phillips, Jonathan E., et al.
Publicado: (2017)

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies
por: Tashkin, Donald P., et al.
Publicado: (2019)

Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol
por: Zarogoulidis, Paul, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5o54ji7mr2qk39p8i97sktauqv